Anteris Technologies Global shareholders approve ASX waiver, provide trial update
PositiveFinancial Markets

Anteris Technologies has received a significant boost as global shareholders approved a waiver from the Australian Securities Exchange (ASX), allowing the company to move forward with its clinical trials. This approval is crucial as it paves the way for Anteris to advance its innovative medical solutions, which could have a substantial impact on patient care. The trial update indicates progress in their research, highlighting the company's commitment to improving healthcare outcomes.
— Curated by the World Pulse Now AI Editorial System